Pfizer v Moderna COVID vaccine patents battle set to continue after UK ruling

  • Moderna claims Pfizer copied mRNA advances and seeks damages for patent infringement
  • High Court invalidates one Moderna patent but upholds another, finding infringement by Pfizer
  • All parties likely to appeal; parallel proceedings ongoing in multiple countries
LONDON, July 2 (Reuters) – Pfizer and Moderna’s legal battle over their rival COVID-19 vaccines looks set to continue after London’s High Court gave a mixed ruling on two of Moderna’s patents, likely prompting a flurry of appeals in the London leg of the litigation.
Pfizer (PFE.N), opens new tab and its German partner BioNTech (22UAy.DE), opens new tab sued Moderna (MRNA.O), opens new tab in London in September 2022, seeking to revoke two patents held by Moderna, which hit back days later alleging its patents had been infringed.
Share On Linkedin
Share Via Email